PolyPid Initiates D-PLEX₁₀₀ NDA Submission to FDA for Surgical Site Infection Prevention

summarizeSummary

PolyPid Ltd. has begun its New Drug Application (NDA) submission to the FDA for D-PLEX₁₀₀, a key step towards commercialization for preventing surgical site infections, with completion expected in Q2 2026.

check_boxKey Events

• NDA Submission Initiated

  PolyPid has started the New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for D-PLEX₁₀₀, aimed at preventing surgical site infections (SSIs) in colorectal surgery patients.

• Rolling Review Under Fast Track

  The NDA is being submitted under the FDA's Fast Track designation, allowing for a rolling review process. The Chemistry, Manufacturing and Controls (CMC) and nonclinical sections have been submitted, with the clinical section expected in Q2 2026.

• Follows Positive Phase 3 Results

  This submission follows positive results from the Phase 3 SHIELD II trial, where D-PLEX₁₀₀ achieved a statistically significant 60% relative risk reduction in SSI incidence.

• Commercialization Partnership Discussions

  The company is actively advancing discussions for a U.S. commercialization partnership for D-PLEX₁₀₀.

auto_awesomeAnalysis

PolyPid Ltd. has commenced the New Drug Application (NDA) submission for its lead product candidate, D-PLEX₁₀₀, to the FDA. This is a critical regulatory milestone for the company, moving its primary asset closer to potential commercialization. The Fast Track designation allows for a rolling review, which could expedite the approval process. Given the positive Phase 3 SHIELD II trial results and Breakthrough Therapy Designation, this submission significantly de-risks the product's path to market. For a company of PolyPid's size, successful NDA submission and potential approval are transformative events, further bolstered by ongoing discussions for a U.S. commercialization partnership.